Draft FDA Guidance Dec 2013 [Regulatives / Guidelines]

posted by jag009  – NJ, 2013-12-09 23:31 (4585 d 00:28 ago) – Posting: # 12027
Views: 20,290

Hi,

❝ Oops :no: New FDA states that "For applicants wishing to use variations of these study designs or analysis methods (e.g., a sequential design or scaled-average BE, we recommend that you submit a complete protocol for review and comment before starting the study", it means any Scaled Average BE protocol need to be submitted to FDA before study initiation :crying:.


Hmm.. But shouldn't one inform the agency if they elect to use a different design other than the partial/full RSABE, ABE (and others that FDA has published) anyway? Why is this a disappointment? They just don't want to think outside the box thats all (too many rules and politics to follow?).

At least they stated up front, otherwise they can reject your study at filing if they want to.

John

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
257 visitors (0 registered, 257 guests [including 18 identified bots]).
Forum time: 00:59 CEST (Europe/Vienna)

Most scientists today are devoid of ideas, full of fear, intent on
producing some paltry result so that they can add to the flood
of inane papers that now constitutes “scientific progress”
in many areas.    Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5